An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE)
Latest Information Update: 12 Feb 2021
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Sponsors Indivior
Most Recent Events
- 10 Jun 2020 Status changed from active, no longer recruiting to completed.
- 20 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2019 Status changed from not yet recruiting to recruiting.